Health Canada Sets 180-Day Review Timeline for Generic GLP-1s

Regulatory Review Process

The 180-day timeline represents Health Canada's standard target for generic drug reviews, according to agency officials. This timeframe applies to the scientific assessment portion of the application process and does not include additional administrative steps that may be required.

Health Canada spokesperson confirmed that this timeline is shorter than similar review processes in other jurisdictions, positioning Canada as having a relatively expedited generic drug approval pathway.

Nine Applications Under Review

As of December 2025, Health Canada received nine submissions for generic versions of semaglutide, the active ingredient in Ozempic and Wegovy. The applications include submissions from:

• Sandoz Canada
• Apotex Inc.
• Teva Pharmaceuticals
• Taro Pharmaceuticals
• Aspen Pharmacare
• Vimy Pharma
• Three additional undisclosed companies

Each application undergoes individual scientific review, meaning approval timelines may vary between manufacturers even under the same target framework.

Patent Expiry Opens Market

Novo Nordisk's regulatory exclusivity for semaglutide ended on January 4, 2026, officially opening the Canadian market to generic competition. The 180-day review timeline suggests the earliest generic approvals could occur by mid-2026, assuming applications were submitted immediately after patent expiry.

However, the actual market launch of generic products will depend on additional factors including manufacturing readiness, supply chain preparation, and final regulatory clearances beyond the initial scientific review.

Industry Implications

The standardized timeline provides pharmaceutical companies with clearer expectations for their generic semaglutide development programs. Several manufacturers have indicated they are preparing production facilities in anticipation of regulatory approval.

Vimy Pharma, which focuses on Canadian-made pharmaceuticals, expects to file its application in the coming weeks and could benefit from the streamlined review process for domestically manufactured products.

Canadian patients and healthcare providers can track generic application progress through Health Canada's public submissions database, which provides regular updates on review status for all applications under assessment.

Market Access Considerations

While Health Canada's review timeline offers regulatory clarity, actual patient access to generic alternatives will depend on additional factors including provincial formulary decisions, insurance coverage determinations, and pharmacy distribution agreements.

Healthcare industry analysts expect generic competition to significantly impact GLP-1 medication pricing in Canada, though the extent of cost reductions will depend on the number of approved manufacturers and their pricing strategies.

Patients seeking current pricing information for brand-name GLP-1 medications can use our generic semaglutide tracker to monitor approval progress and receive updates when generic options become available.